Breast cancer vaccines: current research and future prospects

References

• Ioannides CG, Fisk B, Jerome KR et al Cytotoxic T-cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol 151(7), 3693–3703 (1993).
   Google Scholar
• Disis ML, Calenoff E, McLaughlin G et al Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54(1), 16–20 (1994).
   Google Scholar
• Disis ML, Pupa SM, Gralow JR et al High- titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol 15(11), 3363–3367 (1997).
   Google Scholar
• Toso JF, Oei C, Oshidari F et al. MAGE-1- specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res. 56(1), 16–20 (1996).
   Google Scholar
• Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G. Incidence of de nova breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346 (8978), 796–798 (1995).
   Google Scholar
• Burchell J, Gendler S, Taylor- Papadimitriou J et al Development and characterization of breast cancer reactive monoclonal antibodies directed to the core of the human milk mucin. Cancer Res. 47, 5476–5482 (1987).
   PubMed Web of Science ®Google Scholar
• Zotter S, Hageman PC, I rissnitzer A , Mooi WJ, Kilgers J. Tissue and Tumour distribution of human polymorphic epithelial mucin. Cancer Rev11,55–101 (1988).
   Google Scholar
• Burchell J, Taylor-Papadimitriou J, Boshell M, Gencller S, Duhig TA. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Cancer 44, 691–696 (1989).
   Google Scholar
• von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. j Clin. Oncol 18(3), 574–583 (2000).
   Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Natum Merl 4(1), 43–49 (1998).
   Google Scholar
• Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunise against breast cancer? Cancer Res. 55, 2257–2261 (1995).
   Google Scholar
• Apostolopoulos V, Popovski V, McKenzie IFC. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUCl-mannan fusion protein (M-FP). I Immunother. 21, 109–113 (1998).
   Google Scholar
• Apostolopoulos V, Xing PX, McKenzie IFC. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res. 54,5186-5193 (1994).
   Google Scholar
• Ding L, Lalani EN, Reddish M et al Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother. 36,9–17 (1993).
   PubMed Web of Science ®Google Scholar
• Graham RA, Burchell J, Beverley P, Taylor- Papadimitriou J. Intramuscular immunization with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int.j Cancer 65,664–670 (1996).
   Google Scholar
• Zhang S, Greber LA, Helling F et al. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res. 56,3315–3319 (1996).
   PubMed Web of Science ®Google Scholar
• Gilewski T, Adluri S, Ragupathi G et al Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6(5), 1693–1701 (2000).
   Google Scholar
• Karanikas V, Thynne G, Mitchell P et al. Mannin mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. I /mmunother. 24(2), 172–183 (2001).
   Google Scholar
• Carmon L, El-Shami KM, Paz A et al. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x 132 microglobulin (I32m) null mice transgenic for a chimeric HLA-A2.1/Db-I32 microglobulin single chain. int. j Cancer 85(3), 391–397 (2000).
   Google Scholar
• Pietersz GA, Li W Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 18(19), 2059-2071 (2000).
   Google Scholar
• Vogel C, Sandmaier B, Burris H et al THERATOPETm (STn-KLH) with Detox rm-B stable emulsion for treatment of metastatic breast cancer following first-line chemotherapy. Proc. Ann. Meet. Am. Soc. Clin. Oncol 18, A1761 (1999).
   Google Scholar
• Sandmaier BM, Oparin DV, Holmberg LA et al Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue and immunization with Theratope STn-KLH cancer vaccine. j Immunother. 22(1), 54–66(1999).
   Google Scholar
• Miles DW, Towlson KE, Graham R et al. A randomised Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. Cancer 74 (8), 1292–1296 (1996).
   Google Scholar
• MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. Immunother. Emphasis Tumor Immunol 19(4), 309–316 (1996).
   Google Scholar
• Holmberg LA, Oparin DV, Gooley T et al Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. 25(12), 1233–1241 (2000).
   Google Scholar
• Scholl SM, Balloul JM, Le Goc G et al Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. Immunother. 23(5), 570–580 (2000).
   Google Scholar
• Plunkett TA, Windmill E, Acres RB, Taylor-Papadimitriou J, Miles DW. A Phase II study of a gene-modified vaccinia virus expressing MUC1 and 11–2 (TG1031) in patients with metastatic breast cancer. BE Cancer 85 (Suppl. 1), 25 (2001).
   Google Scholar
• Nussey F, Waterfall M, Samuel K, Atkinson A, Leonard R. Autologous MUC-1 pulsed dendritic cells are a safe, feasible treatment approach in patients with cancer and are associated with cellular immune responses. Br.Cancer 85 (Suppl. 1), 26 (2001).
   Google Scholar
• Correa I, Plunkett TA. Update on HER-2 as a target for cancer therapy HER2/neu peptides as tumour vaccines for T-cell recognition. Breast Cancer Res. 3,399–403 (2001).
   Google Scholar
• Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res. Brat 62 (3), 245–252 (2000).
   Google Scholar
• Disis ML, Schiffman K, Gooley TA et al Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6(4), 1347–1350 (2000).
   Google Scholar
• Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102–3108 (2000).
   PubMed Web of Science ®Google Scholar
• Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5(6), 1289–1297 (1999).
   Google Scholar
• Knutson KL, Schiffman K, Rinn K, Disis ML. Immunotherapeutic approaches for the treatment of breast cancer. j Mammary Gland Biology Neoplasia 4(4), 353–365 (1999).
   Google Scholar
• Murray JL, Przepiorka D, Ioannides CG. Clinical trials of HER-2/neu-specific vaccines. Semin. Oncol 27(6 Suppl. 11), 71–75 (2000).
   Google Scholar
• Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T-lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 58(21), 4902–4908 (1998).
   Google Scholar
• Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60(14), 3782–3789 (2000).
   Google Scholar
• Yip YL, Smith G, Koch J, Dubel S, Ward RL. Identification of epitope regions recognized by tumor inhibitory and stimulatory antiErbB-2 monoclonal antibodies: implications for vaccine design. Immunol 166(8), 5271–5278 (2001).
   Google Scholar
• Scanlan MJ, Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. 3(2), 95–98 (1902).
   Google Scholar
• Machias JP, Reilly RT, Emens LA et al Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61(9), 3689–3697 (2001).
   Google Scholar
• Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. CI.117: Opin. Mal Ther. 1(1), 98–103 (1999).
   Google Scholar
• Bhattacharya-Chatterjee M, Chatterjee SK, Foon IKA. The anti-idiotype vaccines for immunotherapy. Cum Opin. Mol Ther. 3(1), 63–69 (2001).
   Google Scholar
• Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM. Biological therapies for breast carcinoma: concepts for improvement in survival. Sernin. Oncol 26(4 Suppl. 12), 28–40 (1999).
   Google Scholar
• Jager E, Jager D, Knuth A. Strategies for the development of vaccines to treat breast cancer. Rec. Res. Cancer Res. 152,94–102 (1998).
   Google Scholar
• Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. j Gun. Invest. 107(4), 477–484 (2001).
   Google Scholar
• Morse MA. Technology evaluation: Theratope, Biomira, Inc. Gun: Opin. Mol. Ther. 2(4), 453–458 (2000).
   Google Scholar
• von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RII, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int. j Biol. Markers 15 (4), 343–356 (2000).
   Google Scholar